UCBJY:OTCMKTS
UCB Unsponsored Belgium ADR
US$ १३६.६५
arrow_upward
+०.८८%(+१.१९) 1D
जुलाई १७, १६:००:०० GMT-४ · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UCBJY...
Open
US$ १३५.११
High
US$ १३७.२४
Low
US$ १३४.८७
Mkt. cap
४६.०६ अरब
Avg. vol.
३१.४० हजार
Volume
३३.५१ हजार
52-wk high
US$ १६८.७६
52-wk low
US$ १००.४१
Beta
०.५६
Shares outstanding
३८.९० करोड
No. of employees
१० हजार
Open
US$ १३५.११
High
US$ १३७.२४
Low
US$ १३४.८७
Mkt. cap
४६.०६ अरब
Avg. vol.
३१.४० हजार
Volume
३३.५१ हजार
52-wk high
US$ १६८.७६
52-wk low
US$ १००.४१
Beta
०.५६
Shares outstanding
३८.९० करोड
No. of employees
१० हजार
News stories
From sources across the web
ad-hoc-news.de
·
३ घण्टा पहिले
UCB stock holds steady as latest epilepsy data underpins guidance
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB Unsponsored Belgium ADR
AI content may include mistakes. Learn more